Analysts expect Sutro Biopharma, Inc. (NASDAQ:STRO) to report $-0.64 EPS on November, 13.They anticipate $20.62 EPS change or 96.99 % from last quarter’s $-21.26 EPS. After having $-0.60 EPS previously, Sutro Biopharma, Inc.’s analysts see 6.67 % EPS growth. The stock decreased 0.67% or $0.07 during the last trading session, reaching $10.38. About 2,640 shares traded. Sutro Biopharma, Inc. (NASDAQ:STRO) has 0.00% since November 7, 2018 and is . It has by 0.00% the S&P500.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. The company has market cap of $239.67 million. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. It currently has negative earnings. The company's product candidates include STRO-001, an antibody-drug conjugate directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.
More notable recent Sutro Biopharma, Inc. (NASDAQ:STRO) news were published by: Seekingalpha.com which released: “Stocks To Watch: Apple Makes Its Video-Streaming Move – Seeking Alpha” on March 23, 2019, also Seekingalpha.com with their article: “Celgene backs away from collaboration programs with Sutro – Seeking Alpha” published on May 07, 2019, Prnewswire.com published: “Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer – PRNewswire” on October 29, 2019. More interesting news about Sutro Biopharma, Inc. (NASDAQ:STRO) were released by: Finance.Yahoo.com and their article: “Introducing Sutro Biopharma (NASDAQ:STRO), The Stock That Dropped 15% In The Last Year – Yahoo Finance” published on October 30, 2019 as well as Seekingalpha.com‘s news article titled: “Healthcare dominate midday movers – Seeking Alpha” with publication date: October 07, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.